Anti-Aging

Vesilute

Also known as: ED Dipeptide, Glu-Asp, L-Glutamyl-L-Aspartic Acid

Preclinical
Share:

Key Facts: Vesilute

Category
Anti-Aging
FDA Status
Not FDA Approved
Clinical Status
Preclinical - Limited human studies, available as supplement in some regions
Administration
Oral capsules
Typical Dose
1-2 capsules (10-20 mg) daily
Frequency
1-2x daily, before meals
Duration
30-day courses, repeat after 4-6 months
Also Known As
ED Dipeptide, Glu-Asp, L-Glutamyl-L-Aspartic Acid

Mechanism of Action

The claimed mechanism is the generic Khavinson one applied to bladder tissue: a very small peptide that can enter the cell nucleus, interact with chromatin and gene promoter regions, and adjust the expression of genes involved in bladder wall and smooth-muscle function. The marketing narrative adds heterochromatin decondensation, reactivation of genes silenced with age, and reduced chronic inflammation. None of this is supported by published experiments on this specific compound. Treat the entire mechanism as an unverified hypothesis borrowed from related peptides, not an established pathway for Vesilute itself.

Research Summary

This is where Vesilute falls apart on scrutiny. A literature search turns up no controlled studies, no animal data, and no human trials carried out on a peptide named Vesilute. The supportive-sounding claims about bladder and prostate function are reasoned by analogy from other Khavinson cytomedin and cytogen peptides, which themselves rest largely on a single research lineage with limited independent replication. Because even the basic sequence is reported inconsistently across suppliers, you cannot be confident two products labeled Vesilute are the same molecule. There is no safety or efficacy evidence to support using it for urinary symptoms, bladder health, or anything else. Anyone presenting Vesilute as proven is overstating an almost entirely unstudied product.

Trial Progress:Preclinical
Pre
I
II
III
IV
FDA

Dosing Information

Preclinical·Limited published research, primarily anecdotal

Typical Dosing

Community experience

Common Dose

1-2 capsules (10-20 mg) daily

Range

10-20 mg per day

Frequency

1-2x daily, before meals

Khavinson bioregulator for urogenital support. Often used in 30-day cycles. May be combined with Prostamax for prostate support in men. Limited Western research available.

Research Dosing

Scientific studies

Khavinson bioregulator dosing

Duration

30-day courses, repeat after 4-6 months

Administration

Oral capsules

Timing & Administration

Best Time to Take

Morning, before meals

1-2 times daily

Food Recommendation

With or without food

Why This Timing?

Bioregulator peptides typically taken morning on empty stomach for optimal absorption.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • Generally well-tolerated
  • Limited safety data in Western literature
  • Individual intolerance possible
  • Unknown long-term effects

References

Research This Peptide Further

Frequently Asked Questions

What does Vesilute do?

Vesilute is marketed as a Khavinson-style short peptide bioregulator aimed at the urinary bladder and lower urinary tract. Vendor sources cannot even agree on its sequence: some list a Glu-Asp dipeptide, others a Lys-Glu-Asp tripeptide. There are no approvals and, importantly, no peer-reviewed studies published specifically on a peptide called Vesilute, so almost everything written about it is extrapolated from the broader bioregulator family rather than direct evidence.

How does Vesilute work?

The claimed mechanism is the generic Khavinson one applied to bladder tissue: a very small peptide that can enter the cell nucleus, interact with chromatin and gene promoter regions, and adjust the expression of genes involved in bladder wall and smooth-muscle function. The marketing narrative adds heterochromatin decondensation, reactivation of genes silenced with age, and reduced chronic inflammation. None of this is supported by published experiments on this specific compound. Treat the entire mechanism as an unverified hypothesis borrowed from related peptides, not an established pathway for Vesilute itself.

Is Vesilute FDA approved?

No, Vesilute is not currently FDA approved. Current status: Preclinical - Limited human studies, available as supplement in some regions

What are the side effects of Vesilute?

Reported side effects include: Generally well-tolerated, Limited safety data in Western literature, Individual intolerance possible, Unknown long-term effects. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Vesilute?

Community-reported common dose: 1-2 capsules (10-20 mg) daily (1-2x daily, before meals). Range: 10-20 mg per day. Administration: Oral capsules. Community-reported doses. Not FDA approved. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Vesilute or used in similar applications.

Humanin

Preclinical

Humanin is a 24-amino-acid peptide encoded inside mitochondrial DNA (in the 16S rRNA gene), discovered in 2001 and named for its ability to protect human neurons from Alzheimer-related cell death. It was the first member of the mitochondrial-derived peptide family and is studied mainly for neuroprotection, cell survival, and metabolic and age-related disease. The honest status: it has the deepest preclinical evidence base of any mitochondrial peptide, but human therapeutic trials are essentially absent.

Anti-Aging

FOXO4-DRI

Preclinical

FOXO4-DRI is an experimental senolytic peptide, meaning it is designed to kill off worn-out 'zombie' cells (senescent cells) while leaving healthy ones alone. It comes from a single influential 2017 mouse study and is engineered with a clever stability trick. It has never been tested in a human clinical trial, so anything beyond 'promising in mice' is speculation.

Anti-Aging

Glutathione

Clinical Trials

Glutathione is the body's main intracellular antioxidant, a tripeptide of glutamate, cysteine, and glycine (often written GSH). It is sold as oral, IV, topical, and inhaled products and marketed for everything from detox and immune support to skin lightening, but its real, evidence-backed role is as a redox buffer that neutralizes oxidative stress and supports liver detoxification. Some clinical evidence exists for specific uses, while many popular claims, especially IV skin whitening, rest on weak or risky data.

Anti-Aging

DSIP

Clinical Trials

DSIP, or delta sleep-inducing peptide, is a small naturally occurring nonapeptide (sequence Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in the 1970s from the blood of sleeping rabbits. As the name suggests, it was named for its ability to promote delta-wave (deep, slow-wave) sleep in animals. Despite five decades of study it has no regulatory approval and the human evidence for it as a sleep aid is weak and inconsistent.

Anti-Aging

NAD+ Precursors

Clinical Trials

NAD+ precursors are not peptides. They are small molecules, mainly nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN), that the body converts into NAD+, a coenzyme every cell needs to make energy and run repair enzymes. NAD+ falls with age, so these precursors are sold as anti-aging and metabolic supplements. Human trials confirm they reliably raise blood NAD+ levels, but clear proof of real health benefits in people is still missing.

Anti-Aging

SS-31

FDA

SS-31 (sequence D-Arg-Dmt-Lys-Phe-NH2), known generically as elamipretide and sold as FORZINITY, is a synthetic tetrapeptide that homes in on the energy-producing machinery inside your cells. It works by binding cardiolipin, a fat unique to the inner mitochondrial membrane, to help mitochondria run cleaner and make more ATP with less oxidative damage. This is the rare research peptide with a real regulatory finish line: the FDA granted it accelerated approval in September 2025 for Barth syndrome, though it has failed several other major trials.

Anti-Aging

Want updates on Vesilute research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.